Genflow Biosciences Stock Price, News & Analysis

Genflow Biosciences (OTCQB:GENFF), Europe's only publicly listed longevity company, has filed for patent examination in China for its SIRT6 Variants targeting Non-Alcoholic Steatohepatitis (NASH). The patent application covers proprietary variants of the SIRT6 gene designed to address NASH, a severe progressive liver disease with limited treatment options.

This strategic move strengthens Genflow's global intellectual property portfolio and demonstrates its commitment to expanding its presence in one of the world's largest healthcare markets. The company aims to develop innovative SIRT6-based therapies to transform NASH treatment.

Genflow Biosciences (OTCQB:GENFF), Europe's only publicly listed longevity company, has signed two Confidential Disclosure Agreements (CDAs) with leading animal health companies. The agreements facilitate data exchange and discussions for potential collaborations leveraging Genflow's proprietary SIRT6-centenarian gene therapy platform in the companion animal market.

The company's ongoing GF-1004 Dog Aging study with beagles has reported no adverse events to date. These partnerships could accelerate Genflow's path to commercialization by providing access to global scale, regulatory expertise, and commercial infrastructure, potentially leading to licensing agreements in the animal health sector.

Genflow Biosciences (OTCQB:GENFF), Europe's only public longevity company, has reported positive progress in its Dog Aging study (GF-1004), testing a novel SIRT6-centenarian gene therapy. The trial involves 28 beagles aged 10+ years, with treatment administered in March 2025 showing no adverse effects.

The study aims to evaluate the therapy's potential in extending lifespan and improving quality of life in companion animals. Key objectives include validating safety, demonstrating benefits like reduced biological age, increased muscle strength, enhanced mitochondrial function, and improved coat quality. The five-month follow-up period will conclude in January 2026.

The successful completion of this trial could lead to a licensing agreement with a major Animal Health company and potentially unlock future applications in human longevity therapeutics.

Genflow Biosciences (OTCQB:GENFF), Europe's only public longevity company, reported progress on two key programs. For GF-1002, the company has initiated CMC work with Exothera for GMP-compliant clinical supply production, while conducting pivotal efficacy studies for MASH treatment through CRO partners Physiogenex and Accelera. This work supports their upcoming European Clinical Trial Authorisation submission.

For GF-1004, Genflow submitted a protocol amendment to their ongoing proof-of-concept trial in aged dogs, specifying IV dose rates for their SIRT6-centenarian gene therapy to enhance safety and delivery consistency. The trial, launched in March with Syngene, aims to evaluate the therapy's impact on age-related decline.

Genflow Biosciences (OTCQB:GENFF), Europe's only publicly listed longevity company, has confirmed its previously announced €4 million non-dilutive grant from Belgium's Wallonia Region. The funding will support the development of GF-1002, the company's lead gene therapy candidate for treating Metabolic Associated Steatohepatitis (MASH).

The grant covers a three-year development program aligned with Genflow's clinical roadmap. While initial disbursement awaits administrative procedures, the company has ensured the GF-1002 program continues without interruption or delays to planned research and development activities.

Genflow Biosciences (GENFF), Europe's only public longevity company, reports significant progress in its SIRT6-centenarian gene therapy programs. The company signed an MSA with CER Groupe for pre-clinical services and advanced its patent applications in Europe and Japan. Key program updates include: successful initial production of GF-1002 for MASH treatment with CDMO partner Exothera SA; development of a liver organoid model for Werner Syndrome therapy (GF-1003); commencement of a dog aging clinical trial (GF-1004) with 28 dogs; advancement in sarcopenia treatment (GF-1005) with four drug candidates; and launch of a new ophthalmology program. The company strengthened its research capabilities through partnerships, including an AI collaboration with Heureka Labs, and continues to receive government grant support for multiple programs.

Genflow Biosciences (OTCQB:GENFF), Europe's only publicly listed longevity company, has signed a Master Service Agreement (MSA) with CER Groupe, a private Belgian research center. The agreement formalizes their existing partnership and establishes a framework for accelerating Genflow's pre-IND gene therapy programs. The collaboration will focus on developing, producing, and characterizing gene therapy candidates while implementing standardized project management systems. CER Groupe brings ISO and GxP-compliant facilities and integrated bioproduction and pre-clinical services to the partnership.

Genflow Biosciences (LSE:GENF)(OTCQB:GENFF) announces the advancement of its SIRT6-related patent application to the national examination phase by the Japanese Patent Office. The patent, titled "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases," was filed in May 2022 and is jointly owned by the University of Rochester, Columbia University, and Albert Einstein College of Medicine, with Genflow holding exclusive licensing rights.

The patent covers novel SIRT6 gene variants crucial for genomic stability, metabolic regulation, and healthy aging, forming the foundation of Genflow's therapeutic platform. This advancement in Japan, a key market with a rapidly aging population, represents a significant step in the company's international patent protection strategy.

Dr Moayyed Al-Qurtas has acquired a significant stake in Genflow Biosciences (GENFF), reaching a 4.45% ownership of voting rights in the company. The threshold crossing occurred on May 9, 2025, and was reported to the company on May 12, 2025. This notification was made in accordance with the UK's Disclosure Guidance and Transparency Rules (DTR5). The acquisition was made through direct ownership of shares, with no financial instruments or indirect holdings involved.